|
A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C |
Buti M, Medina M, Casado M A, Wong J B, Fosbrook L, Esteban R |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Buti M, Medina M, Casado M A, Wong J B, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics 2003; 17(5): 687-694 Indexing Status Subject indexing assigned by NLM MeSH Adult; Antiviral Agents /economics /therapeutic use; Cost-Benefit Analysis; Female; Hepatitis C, Chronic /drug therapy /economics; Humans; Interferon Alfa-2a; Interferon Alfa-2b /economics /therapeutic use; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Ribavirin /therapeutic use; Sensitivity and Specificity; Treatment Outcome AccessionNumber 22003000605 Date bibliographic record published 30/04/2003 |
|
|
|